The investment bank, which maintained its $60 price target for the company's stock, said it is looking for signs of revenue acceleration.
The investment bank initiated coverage on Rosetta Genomics and Veracyte, rating the molecular diagnostic firms' shares speculative buy and buy, respectively.
The company also said that its cash burn rate for Q2 is estimated to be about $4.8 million, or $1.3 million more than its average cash burn.
Cantor will offer PacBio's stock in an "at-the-market" offering, though the investment bank may also sell the shares through other methods.
CNN reports that researchers have tied a new variant to opioid addiction risk.
Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.
An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.
In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.